Overview of Ftc Actions in Pharmaceutical Products and Distribution*

Total Page:16

File Type:pdf, Size:1020Kb

Overview of Ftc Actions in Pharmaceutical Products and Distribution* OVERVIEW OF FTC ACTIONS IN PHARMACEUTICAL PRODUCTS AND DISTRIBUTION* Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Kara Monahan Deputy Assistant Director August 2020 * Actions involving health care services and products are contained in a separate document, Overview of FTC Actions in Health Care Services and Products. Information about advisory opinions in the health care and pharmaceutical sectors is contained in the document Topic and Yearly Indices of Health Care Antitrust Advisory Opinions by Commission and by Staff. TABLE OF CONTENTS I. INTRODUCTION ...............................................................................................................1 II. CONDUCT INVOLVING PHARMACEUTICAL PRODUCTS .......................................3 A. Monopolization ........................................................................................................3 B. Agreements Not to Compete ..................................................................................15 III. CONDUCT INVOLVING PHARMACEUTICAL DISTRIBUTION ..............................20 A. Monopolization ......................................................................................................20 B. Agreements on Price and Price-Related Terms .....................................................21 C. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing................................................................................................................27 IV. MERGERS INVOLVING PHARMACEUTICAL PRODUCTS .....................................27 A. Horizontal Mergers between Direct Competitors ..................................................27 B. Potential Competition Mergers ..............................................................................63 C. Innovation Market Mergers ...................................................................................71 V. MERGERS INVOLVING PHARMACEUTICAL DISTRIBUTION ..............................73 A. Horizontal Mergers between Direct Competitors ..................................................73 B. Vertical Mergers ....................................................................................................77 VI. INDUSTRY GUIDANCE STATEMENTS INVOLVING PHARMACEUTICAL PRODUCTS AND DISTRIBUTION ................................................................................78 A. Advisory Opinions .................................................................................................78 B. Citizen Petition to the Food and Drug Administration ..........................................78 C. FTC Amendments to the Premerger Notification Rules Related to the Transfer of Exclusive Patent Rights in the Pharmaceutical Industry ....................79 D. 2004 Report: Improving Health Care: A Dose of Competition .............................79 VII. AMICUS BRIEFS INVOLVING PHARMACEUTICAL PRODUCTS AND DISTRIBUTION................................................................................................................80 A. Reverse Payment ....................................................................................................80 B. Market Definition...................................................................................................85 C. Product Hopping ....................................................................................................86 i D. Restricted Distribution/REMS ...............................................................................87 E. Patent Issues ...........................................................................................................88 F. Noerr-Pennington Doctrine ....................................................................................90 G. Regulatory Issues ...................................................................................................91 VIII. INDEX - TABLE OF CASES AND BRIEFS ...................................................................93 ii FTC ACTIONS IN PHARMACEUTICAL PRODUCTS AND DISTRIBUTION1 I. INTRODUCTION The Federal Trade Commission is a law enforcement agency charged by Congress with protecting the public against anticompetitive behavior and deceptive and unfair trade practices. The FTC’s antitrust arm, the Bureau of Competition, is responsible for investigating and prosecuting “unfair methods of competition” which violate the FTC Act. The FTC shares with the Department of Justice responsibility for prosecuting violations of the Sherman Act and the Clayton Act. When litigation becomes necessary, the FTC may conduct an administrative adjudication before an FTC Administrative Law Judge. This provides the opportunity for matters raising complex legal and economic issues to be heard, in the first instance, in a forum specially suited for dealing with such matters. Appeals from Commission decisions are taken directly to the federal courts of appeal. The Commission also has the authority under Section 13(b) of the FTC Act to seek a preliminary injunction in federal district court whenever the Commission has reason to believe that a party is violating, or is about to violate, any provision of law enforced by the FTC. Such preliminary injunctions are intended to preserve the status quo, or to prevent further consumer harm, pending administrative adjudication before the Commission. Additionally, the Commission has the authority to seek a permanent injunction in federal district court in a “proper case” pursuant to section 13(b) of the FTC Act. In the mid-1970's, the FTC formed a division within the Bureau of Competition to investigate potential antitrust violations involving health care. The Health Care Division consists of approximately 40 lawyers and investigators who work exclusively on health care antitrust matters, including non-merger matters involving the pharmaceutical industry. The Mergers I Division investigates mergers involving pharmaceutical products. FTC actions involving pharmaceutical products and distribution2 are summarized below.3 The summaries are intended to provide a brief overview of FTC enforcement actions. They do not reflect all subsequent actions taken by the Commission or the parties. The Commission and its staff have also 1 This summary has been prepared by the FTC Health Care Division staff, and has not been reviewed or approved by the Commission or the Bureau of Competition. Section IV describes FTC enforcement involving mergers in the pharmaceutical industry, which are primarily conducted by the Mergers I Division of the Bureau of Competition. 2 Actions involving health care services and products are contained in a separate document, Overview of FTC Actions in Health Care Services and Products, https://www.ftc.gov/tips-advice/competition-guidance/industry- guidance/health-care. 3 Commission complaints and orders issued since March 1996 are available at the FTC’s website at http://www.ftc.gov/tips-advice/competition-guidance/industry-guidance/health-care (under the “Cases” drop down menu). 1 responded to numerous requests for guidance from health care industry participants through, among other things, the advisory opinion letter process.4 For further information about matters handled by the FTC’s Health Care Division, or to lodge complaints about suspected antitrust violations, please write, call, e-mail,5 or fax this office as follows: Mailing Address: Health Care Division Bureau of Competition Federal Trade Commission Washington, DC 20580 Telephone Number: (202)-326-3759, (202)-326-3670, or (202)-326-2018 E-Mail: [email protected] Fax Number: (202)-326-3384 For further information about pharmaceutical mergers handled by the FTC’s Mergers I Division, please write, call, e-mail, or fax the Mergers I Division as follows: Mailing Address: Mergers I Division Bureau of Competition Federal Trade Commission Washington, DC 20580 Telephone Number: (202)-326-3106, (202)-326-3506, or (202)-326-2118 E-Mail: [email protected] Fax Number: (202)-326-2655 4 Information regarding advisory opinions is set forth in the Topic and Yearly Indices of Health Care Advisory Opinions by Commission and by Staff. The indices, the advisory opinions, and other information relating to the Commission’s advisory opinion program are also available at the FTC’s website at http://www.ftc.gov/tips- advice/competition-guidance/industry-guidance/health-care. 5 Note that e-mail is not secure. Confidential information should be marked “Confidential” and sent via regular mail. To learn how we may use the information you provide, please read our Privacy Policy. 2 II. CONDUCT INVOLVING PHARMACEUTICAL PRODUCTS A. Monopolization Federal Trade Commission, et al. v. Vyera Pharmaceuticals, LLC, et al., No. 20-cv-00706, FTC File No. 161-0001 (complaint issued January 27, 2020; amended complaint filed on April 14, 2020) (https://www.ftc.gov/news-events/press-releases/2020/04/six-more-states-join-ftc-ny- attorney-generals-case-against-vyera). On January 27, 2020, the FTC filed a complaint jointly with the State of New York alleging an elaborate anticompetitive scheme by Vyera Pharmaceuticals, LLC, its parent company Phoenixus AG, its founder Martin Shkreli, and its former CEO Kevin Mulleady to preserve a monopoly for the life-saving drug Daraprim. On April 14, 2020, the FTC and New York filed an amended complaint adding six additional state plaintiffs—California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia.
Recommended publications
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
    [Show full text]
  • PRECEDENTIAL UNITED STATES COURT of APPEALS for the THIRD CIRCUIT ___Nos. 14-4202, 14-4203, 14-4204, 14-4205, 14-4206, 14-46
    Case: 14-4203 Document: 003112598145 Page: 1 Date Filed: 04/19/2017 PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ______ Nos. 14-4202, 14-4203, 14-4204, 14-4205, 14-4206, 14-4602 & 14-4632 ______ IN RE: LIPITOR ANTITRUST LITIGATION Rite Aid Corporation; Rite Aid Hdqtrs. Corporation; JC (PJC) USA, LLC; Maxi Drug, Inc. d/b/a Brooks Pharmacy; Eckerd Corporation, Appellants in No. 14-4202 Walgreen Company; The Kroger Co.; Safeway, Inc.; Supervalu, Inc.; HEB Grocery Company L.P., Appellants in No. 14-4203 Giant Eagle, Inc., Appellant in No. 14-4204 Meijer, Inc.; Meijer Distribution, Inc., Appellants in No. 14-4205 Rochester Drug Co-Operative, Inc.; Stephen L. LaFrance Pharmacy, Inc. d/b/a SAJ Distributors; Burlington Drug Company, Inc.; Value Drug Company; Professional Drug Company, Inc.; American Sales Company LLC, Appellants in No. 14-4206 Case: 14-4203 Document: 003112598145 Page: 2 Date Filed: 04/19/2017 A.F.L.-A.G.C. Building Trades Welfare Plan; Mayor and City Council of Baltimore, Maryland; New Mexico United Food and Commercial Workers Union’s and Employers’ Health and Welfare Trust Fund; Louisiana Health Service Indemnity Company, d/b/a Blue Cross/Blue Shield of Louisiana; Bakers Local 433 Health Fund; Twin Cities Bakery Workers Health and Welfare Fund; Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund; International Brotherhood of Electrical Workers Local 98; New York Hotel Trades Counsel & Hotel Association of New York City, Inc., Health Benefits Fund; Edward Czarnecki; Emilie Heinle; Frank Palter; Andrew Livezey; Edward Ellenson; Jean Ellyne Dougan; Nancy Billington, on behalf of themselves and all others similarly situated, Appellants in No.
    [Show full text]
  • CVS Corporation 2004 Annual Report H Cvrs Narrative 3/17/05 12:18 PM Page +6
    h_cvrs_narrative 3/17/05 12:17 PM Page +3 At CVS, it’s all in a day’s work... CVS Corporation 2004 Annual Report h_cvrs_narrative 3/17/05 12:18 PM Page +6 2:00am Another customer finds relief. From a toddler’s ear infection to a flare up of asthma, illnesses often have little regard for the clock. CVS has been doing its part to help, with approximately 60 percent of our stores offering 24- or extended- hour service. It’s just one of the many ways we make our pharmacy experience “CVS easy.”™ After all, the pharmacy accounts for 70 percent of our overall sales. CVS has a 13.5 percent share of the retail pharmacy market nationally, and we fill one in every five prescriptions in markets where we operate. Thanks to the Pharmacy Service Initiative (PSI) we launched in 2003, CVS is also making sure that prescriptions are “ready when promised”™ at any hour. Our pharmacy initiatives have freed up our pharmacists to spend more time counseling customers as well. As a result, customer service scores posted healthy gains in 2004. To realize similar benefits in the acquired Eckerd stores, we completed the training of more than 11,000 pharmacists and pharmacy support personnel on CVS systems, service processes, and standards. With more than 5,300 retail stores throughout the country and more on the way, CVS is well positioned to benefit from long-term pharmacy growth trends. The U.S. population is aging, healthcare costs are rising, and pharmaceuticals remain often the most cost-effective form of treatment.
    [Show full text]
  • Where to Buy US
    STATE CITY RETAIL ADDRESS AK FAIRBANKS WALGREENS DRUG STORE 1350 SPORTSMAN WAY AK KENAI WAL-MART 10096 KENAI SPUR HWY AK EAGLE WAL-MART 18600 EAGLE RIVER RD AK ANCHORAGE WAL-MART 3101 A ST AK FAIRBANKS WAL-MART 537 JOHANSEN EXPY AK JUNEAU WAL-MART 6525 GLACIER HWY AK ANCHORAGE WAL-MART 7405 DEBARR RD AK ANCHORAGE WAL-MART 8900 OLD SEWARD HWY AR W MEMPHIS WALGREENS DRUG STORE 1800 N MISSOURI ST AZ PHOENIX CVS PHARMACY/REVCO 10 E DUNLAP AVE AZ PARADISE VALLEY CVS PHARMACY/REVCO 10010 N SCOTTSDALE RD AZ CHANDLER CVS PHARMACY/REVCO 1015 E RAY RD AZ SCOTTSDALE CVS PHARMACY/REVCO 10160 E BELL RD AZ TUCSON CVS PHARMACY/REVCO 10650 N ORACLE RD AZ SCOTTSDALE CVS PHARMACY/REVCO 10653 N SCOTTSDALE RD AZ PHOENIX CVS PHARMACY/REVCO 10707 W CAMELBACK RD AZ SUN CITY CVS PHARMACY/REVCO 10720 W BELL RD AZ PEORIA CVS PHARMACY/REVCO 10727 W OLIVE AVE AZ MESA CVS PHARMACY/REVCO 1137 S DOBSON RD AZ YUMA CVS PHARMACY/REVCO 11464 S FORTUNA RD AZ COTTONWOOD CVS PHARMACY/REVCO 1179 S HIGHWAY 260 AZ MESA CVS PHARMACY/REVCO 1212 S GREENFIELD RD AZ PHOENIX CVS PHARMACY/REVCO 12409 N TATUM BLVD AZ PHOENIX CVS PHARMACY/REVCO 125 S 67TH AVE STE 1 AZ PARKER CVS PHARMACY/REVCO 131 W RIVERSIDE DR AZ SURPRISE CVS PHARMACY/REVCO 13870 W GREENWAY RD AZ TEMPE CVS PHARMACY/REVCO 1424 W BASELINE RD AZ SCOTTSDALE CVS PHARMACY/REVCO 14672 N FRANK LLOYD WRIGH AZ PHOENIX CVS PHARMACY/REVCO 1525 N CENTRAL AVE AZ SURPRISE CVS PHARMACY/REVCO 15300 N COTTON LN AZ SURPRISE CVS PHARMACY/REVCO 15474 W GREENWAY RD AZ YUMA CVS PHARMACY/REVCO 1555 S AVENUE B STE B AZ PHOENIX CVS PHARMACY/REVCO
    [Show full text]
  • Net Lease Pharmacy Report March 2018
    Net Lease Pharmacy Report March 2018 NET LEASE PHARMACY INDUSTRY OVERVIEW CVS and Walgreens are the market leaders in the U.S. drugstore industry accounting for more than half of the market share in top metropolitan areas. Over the years, drugstores have evolved into all- encompassing health service providers and as a result have strategically positioned themselves to diversify their portfolios by acquiring key competitors and forging partnerships to protect themselves from growing online threat. Industry demand is driven by an aging population, health issues, and ad- vances in medical treatment. Drugstores rely heavily on their prescription business, which has grown over the years, however same store comparables for front of store sales have decreased. Total 2017 retail sales for prescription drugs filled at pharmacies surpassed $397B* and are speculated to have been upwards of $426B. *Data based on QuintilesIMS National Prescription Audit (NPA) database. Includes new prescriptions and refills of both brand/generic. Source: Kaiser Foundation Definitions Pharmacy Benefits Managers (PBM): Third party companies that provide healthcare management and administration services to insurance companies, Medicare Part D plans, state government employee plans and corporations. e.g. CVS Caremark, Express Scripts. PBMs lever- age economies of scale by negotiating drug prices with drug makers and pharmacies on behalf of larger groups of customers. Chad M. Firsel Daniel Waszak Jason Caplan Zack Hilgendorf Jack Farritor President Senior Vice President Senior Vice President Vice President Vice President 312.269.0220 312.269.0550 312.533.2347 312.533.2348 312.683.9924 [email protected] [email protected] [email protected] [email protected] [email protected] Quantum Real Estate Advisors, Inc.
    [Show full text]
  • Participating Chain Pharmacies
    PARTICIPATING CHAIN PHARMACIES A & P Pharmacy Discount Drug Mart Hy-Vee, Drug Town Network Pharmacy Shoppers Pharmacy ABCO Pharmacy Doc's Drugs Ingles Pharmacy Oncology Pharmacy Services Shoprite Pharmacy Acme Pharmacy Drug Emporium Integrity Healthcare Services P&C Food Market Shurfine Pharmacy Acme, Lucky, Osco, Sav-on Drug Fair Kare Pharmacy Pacmed Clinic Pharmacy Smith's Food & Drug Center Albertson's Pharmacy Duane Reade Kash N' Karry Pharmacy Pamida Pharmacy Snyder Drug Stores Allcare Pharmacy Eagle Pharmacy Kelsey Seybold Clinic Pharmacy Park Nicollet Pharmacy Southern Family Markets Ambulatory Pharmaceutical Services Edgehill Drugs Kerr Drug Pathmark Stadtlander Pharmacy Anchor Pharmacy Express, Thrift, Treasury Keystone Medicine Chest Payless Pharmacy Standard Drug Company Appletree Pharmacy Fagen Pharmacy King Kullen Pharmacy Pediatric Services of America Star Pharmacy Arrow Pharmacy Fairview Pharmacy Kinney Drug's Pharma-Card Statscript Pharmacy Aurora Pharmacy Family Care Pharmacy Kleins Supermarket Pharmacy Pharmacy Plus Steele's Pharmacy B J's Pharmacy Family Drug Klinck, Drug Barn Presbyterian Retail Pharmacy Stop & Shop Pharmacy Bakers Pharmacy Family Fare Klingensmith's Drug Price Chopper Pharmacy Super D Bartell Drugs Family Pharmacy Kmart Pharmacy Price Less Drug Super Food Mart Basha's United Drug Fedco Drug Knight Drugs Price Wise, Piggly Wiggly Super Fresh Pharmacy Bel Air Pharmacy Finast Pharmacy Kohlls Pharmacy Prime Med Pharmacy Super RX Pharmacy Big Bear Pharmacy Food 4 Less Pharmacy Kopp Drug Publix Pharmacy
    [Show full text]
  • Petitoner's Jurisdictional Brief
    IN THE FLORIDA SUPREME COURT S. Ct. Case No.: CASE NO.: 3D05-2253 GARRETT DENT, Petitioner/Plaintiff, vs. DENNIS PHARMACY, INC., Respondent/Defendant. __________________________/ PETITONER’S JURISDICTIONAL BRIEF Respectfully submitted, David S. Wieder, Esq. Fla. Bar No.:153129 David S. Wieder, P.A. Hermelee & Geffin, LLC Counsel for Garrett Dent 25 S.E. 2nd Ave., Suite 1135 Miami, Florida 33131 Telephone: (305) 373-5444 Facsimile: (305) 373-0039 & David Hagen, Esq. Fla. Bar No.: 158143 49 E. Flagler St., PH104 Miami, Florida 33131 Telephone:(305) 373-4200 Facsimile: (305) 403-4900 TABLE OF CONTENTS TABLE OF CONTENTS ii TABLE OF AUTHORITIES iii OTHER AUTHORITIES iv STATEMENT OF THE CASE AND FACTS 1 STATEMENT OF JURISDICTION 2 SUMMARY OF THE ARGUMENT 3 ARGUMENT 4 THE DISTRICT COURTS ARE IN DIRECT CONFLICT REGARDING WHETHER A PHARMACIST HAS A DUTY TO WARN CUSTOMERS OF DANGERS ASSOCIATED WITH A PRESCRIPTION DRUG. 4 THE DISTRICT COURTS ARE IN DIRECT CONFLICT REGARDING WHETHER RELIANCE IS A NECESSARY ELEMENT OF A VOLUNTARY UNDERTAKING CAUSE OF ACTION. 7 THE DISTRICT COURTS ARE IN DIRECT CONFLICT REGARDING WHETHER AN UNIDENTIFIED THIRD PARTY CAN FALL WITHIN A REASONABLE AND FORESEEABLE ZONE OF RISK. 8 THE THIRD DISTRICT COURT EXPRESSLY DECLARED VALID FLA. STAT. §465.003 AND FLA. ADMIN. CODE R. 64B16-27.820. 10 CONCLUSION 10 CERTIFICATE OF TYPE SIZE AND STYLE 11 CERTIFICATE OF SERVICE 12 ii TABLE OF AUTHORITIES Arab Termite and Pest Control v. Jenkins, 409 So. 2d 1039 (Fla. 1982). 2 Cheeks v. Dorsey, 846 So. 2d 1169 (Fla. 4th DCA 2003). 9 Clay Electric v.
    [Show full text]
  • The People Shaping the Industry
    DRSN041208p81 4/21/08 3:46 PM Page 81 ANNUALANNUAL TheREPORT people shaping the industry --------------------------------2 Chains expand focus amid uncertain economy -------------15 The Drug Store News Power Rx 50---------------------------16 Mass retailers push pharmacy by expanding programs ---17 Regional players strengthen foothold by finding niche-----18 Supermarkets emphasize health/nutrition connection------19 Drug StoreStore News News www.drugstorenews.comwww.drugstorenews.com 08AprilApril 21, 21, 2008 2008• •81 1 DRSN_042108_p83.qxd 4/9/08 8:47 PM Page 83 08 ANNUALREPORT Bill Baxley, Kerr Drug ill Baxley, senior vice Baxley has been with Kerr for crease inventory.” The big- president of merchandis- more than 40 years, beginning gest long-term challenge? B ing and marketing for as a stock clerk in 1967. After “Constantly reinventing Kerr Kerr Drug, said if he weren’t in graduating from pharmacy Drugs,” he said. the drug store industry, he’d be school in 1971, he began work- Baxley said the most sur- of service to humanity, “devel- ing at Kerr’s Store No. 1 in prising development of the oping goals for peace.” Raleigh, N.C. past year occurred outside Those who know Baxley As a retailer, Baxley said with the “collapse of the finan- probably wouldn’t be surprised his top goal this year is to cial markets,” and of Bear by his altruistic leanings. “improve margin and de- Stearns in particular. Paul Beahm, Wal-Mart aul Beahm, senior vice the healthcare arena, where he’s tinue today, but after a major president and general spent the majority
    [Show full text]
  • Revised January 21, 2016
    RITE AID CORPORATION DISTRIBUTION CENTERS / SHIP–TO-LOCATIONS ENTITY REFERENCE DC SHIP-TO-LOCATIONS / PO DEA NUMBER DUNS NO.+ 4 PREFERRED LTL CARRIER CHARLOTTE DISTRIBUTION CENTER 1776 Statesville Avenue YRC, ESTES, UPS Eckerd Corporation N/A 0145788920053 Charlotte, NC 28206 (704) 371-3653 DAYVILLE DISTRIBUTION CENTER Killingly Oaks Business Park YRC, ESTES, UPS, PJC Distributions Inc 500 Forbes Road N/A 0145788920054 NEW ENGLAND MOTOR Dayville, CT 06241 FREIGHT (860) 779-0632 LIVERPOOL DISTRIBUTION CENTER* YRC, ESTES, UPS, 7245 Henry Clay Boulevard Eckerd Corporation RE0356003 0145788920055 NEW ENGLAND MOTOR Liverpool, NY 13088 FREIGHT (315) 451-5700 x2274 PHILADELPHIA DISTRIBUTION CENTER YRC, ESTES, UPS, 1 Geoffrey Road Thrift Drug Inc N/A 0145788920056 NEW ENGLAND MOTOR Fairless Hills, PA 19030 FREIGHT (215) 428-5917 PERRYMAN DISTRIBUTION CENTER* YRC, ESTES, UPS, 601 Chelsea Road Rite Aid of Maryland Inc RR0236073 0145788920010 NEW ENGLAND MOTOR Aberdeen MD 21001-4306 FREIGHT (410) 297-6363 RITE AID FIXTURE DISTRIBUTION CENTER 325 Welltown Road N/A YRC, ESTES, UPS N/A 0145788920023 Winchester, VA 22603 (540) 662-3552 PONTIAC DISTRIBUTION CENTER* 5400 Perry Drive YRC, ESTES, UPS Perry Drug Stores 002230PIY 0145788920029 Waterford, MI 48329 (248) 674-7770 TUSCALOOSA DISTIBUTION CENTER* 3931 Rice Mine Road NE YRC, ESTES, UPS HARCO Inc RH0231124 0145788920035 Tuscaloosa, AL 35406 (205) 345-7419 x225 POCA DISTRIBUTION CENTER* 160 Jacobson Drive YRC, ESTES, UPS Rite Aid of West Virginia Inc 004569RDY 0145788920050 Poca WV 25159-9772 (304)
    [Show full text]
  • Leveraged Buy out of Revco D S Inc
    2012 Leveraged Buy Out of Revco D S Inc. Group - 4 Department of Finance, University of Dhaka 9/9/2012 Leverage Buyout of Revco D S Inc Submitted To: Dr. Md. Sadiqul Islam Professor Department of Finance University of Dhaka Submitted By: Group no. 4 13th batch Department of Finance University of Dhaka Date of Submission: 09 September, 2012 Group Members Name Roll Mohammed Robiul Alam 13-643 ASM Zakariya 13-578 Rokeya Mahzavin 13-588 Md. Shah Naoaj 13-686 Taslima Akter 13-666 Letter of Transmittal Dr. Md. Sadiqul Islam Professor Department of Finance University Of Dhaka Subject: Submission of Case Report. Dear Sir: With great pleasure and honor we are submitting our case report on ―Leverage Buy Out of Revco D S Inc‖. The case study includes analysis of LBO of Revco. We analyzed the LBO from different viewpoints by using various financial tools and software. We have tried our best to accommodate as much information and relevant issues as possible and follow the instructions that you have given. We would like to thank you for providing us with the opportunity to prepare this case report. Sincerely Yours Group -04 13th batch Department of Finance University of Dhaka Table of Contents 1. Introduction .................................................................................................................................................... 1 1.1. The Company ........................................................................................................................................ 1 1.2. Competition ..........................................................................................................................................
    [Show full text]
  • Script Care Ltd. Participating Chain Pharmacies
    SCRIPT CARE LTD. PARTICIPATING CHAIN PHARMACIES A & P Pharmacy Drug Emporium Kare Pharmacy Park Nicollet Pharmacy Shurfine Pharmacy ABCO Pharmacy Drug Fair Kash N' Karry Pharmacy Pathmark Smith's Food & Drug Center Acme Pharmacy Duane Reade Kelsey Seybold Clinic Pharmacy Payless Pharmacy Snyder Drug Stores Acme, Lucky, Osco, Sav-on Eagle Pharmacy Kerr Drug Pediatric Services of America Southern Family Markets Albertson's Pharmacy Edgehill Drugs Keystone Medicine Chest PharmacPhar-Mor Stadtlander Pharmacy Allcare Pharmacy Express, Thrift, Treasury King Kullen Pharmacy Pharma-Card Standard Drug Company Ambulatory Pharmaceutical ServiceFagen Pharmacy Kinney Drug's Pharmaca Integrative Pharmacy Star Pharmacy Anchor Pharmacy Fairview Pharmacy Kleins Supermarket Pharmacy Pharmacy Plus Statscript Pharmacy Appletree Pharmacy Family Care Pharmacy Klinck, Drug Barn Presbyterian Retail Pharmacy Steele's Pharmacy Arrow Pharmacy Family Drug Klingensmith's Drug Price Chopper Pharmacy Stop & Shop Pharmacy Aurora Pharmacy Family Fare Kmart Pharmacy Price Less Drug Super D B J's Pharmacy Family Pharmacy Knight Drugs Price Wise, Piggly Wiggly Super Food Mart Bakers Pharmacy Fedco Drug Kohlls Pharmacy Prime Med Pharmacy Super Fresh Pharmacy Bartell Drugs Finast Pharmacy Kopp Drug Publix Pharmacy Super RX Pharmacy Basha's United Drug Food 4 Less Pharmacy Kroger Pharmacy QFC Pharmacy Super Sav-On-Drug's Bel Air Pharmacy Food City Pharmacy Lewis Drugs Quality Pharmacy Supersaver Pharmacy, Sentry Drug Bi-Lo Pharmacy Food Lion Pharmacy Lifecheck Drug Quick Chek
    [Show full text]
  • Platte City, Missouri (Kansas City MSA)
    Platte City, Missouri (Kansas City MSA) Offering Memorandum Presented by the Patton | Wiles | Fuller Group of Marcus & Millichap Platte City, Missouri (Kansas City MSA) Exclusively Listed by the Patton / Wiles / Fuller Group of Marcus & Millichap: Dustin Javitch Craig Fuller First Vice President Investments Senior Managing Director Net Leased Properties Group National Retail Group Cleveland Office Cleveland Office P: (216) 264-2025 P: (216) 264-2043 [email protected] [email protected] License: OH SAL.2012000193 License: OH SAL.2008001551 Scott Wiles Erin Patton Senior Managing Director Senior Managing Director National Retail Group National Retail Group Cleveland Office Columbus Office P: (216) 264-2026 P: (614) 360-9035 [email protected] [email protected] License: OH SAL.2005013197 License: OH SAL.2004010274 Absolute Net Lease CVS with 14.25 Years Remaining Located in the Kansas City MSA 20-MI Demographics 1301 Platte Falls Road 512,683 Platte City, MO (Kansas City MSA) 64079 Total Population Investment Highlights Location Highlights $85,217 • Absolute Net Lease CVS with 14.25 Years • Affluent Kansas City Suburb | Average Average Household Income Remaining Located in the Kansas City MSA Household Income $108,200 Within a 5-Mile Radius • 2020 Remodel to the New HealthHUB Concept | ~$450,000 in Tenant Paid • Positioned Along Area’s Major Retail & Improvements Traffic Corridor | Easy Access & Excellent Visibility 1.5% • Rare Rental Increases in Renewal Options | 15% in Option 1
    [Show full text]